During the Slovenian government delegation's visit to Shanghai, the Slovenian Consulate in Shanghai and the Shanghai Municipal Commission for Trade Promotion hosted the "China–Slovenia Business and Investment Forum" on November 4th, 2024. This event brought together senior Slovenian government officials, representatives from economic and trade organizations, and diplomats in China, who delivered speeches at the opening ceremony and engaged in business matchmaking activities. The forum's objective was to enhance communication and cooperation between Chinese and Slovenian enterprises and to encourage Chinese entrepreneurs to explore the European market with Slovenia as a base. As one of the representatives of Chinese enterprises expanding abroad, Porton Pharma Solutions was invited to participate and share its investment experience.

Porton Board Chairman & CEO, Mr. Oliver Ju; Vice President and Board Secretary of Porton, Ms. Pi Wei; VP, Head of Porton Slovenia, Mr. Wang Fengping; along with Deputy General Manager of the Sales & Marketing Center, Dr. Bai Yingjun, attended the forum. They engaged in a friendly meeting with the Slovenian Minister of Economy, H.E. Mr. Matjaž Han, and the Slovenian Ambassador to China, H.E. Mr. Boštjan Malovrh.

The journey of a thousand miles begins with a single step, and Porton remains steadfast in its commitment to global development by actively advancing its strategic international expansion. On May 22nd, 2024, Porton proudly inaugurated its first R&D center in Europe, located in Mengeš, Slovenia, marking a significant milestone following its acquisition of the US-based J-STAR Research Inc. in 2017. With an initial investment of €50 million, this Slovenian R&D and manufacturing facility is dedicated to providing global clients with customized R&D and manufacturing services for small molecule APIs. These comprehensive services include synthetic route development, process optimization, analytical method development and validation, along with process scale-up and production. The pilot plant is anticipated to become operational by 2026.

Slovenia has been actively developing and supporting the biomedical industry. With backing from the Slovenian government, the Embassy of Slovenia in China, and Chinese governmental departments, Porton, as a global leading CDMO, is firmly committed to promoting internationalization and vigorously developing and supporting the Slovenian biomedical industry. We continue to advance our journey of sustainable development in Slovenia by focusing on being Green, Creative, and Smart.